| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/20410/2013 (28.01.13) |
| Publication Date | 28/01/2013 |
| Content Type | News |
|
The European Medicines Agency (EMA), in January 2013, was aksed by France to review third- and fourth-generation combined oral contraceptives to determine whether there was a need to restrict the use of these medicines to women who could not take other combined oral contraceptives. France made this request amid initiatives to reduce the use of third- and fourth-generation combined oral contraceptives by French women in favour of using second-generation oral contraceptives. It is well established that combined contraceptives carry a very rare risk of venous thromboembolism (VTE or blood clots). |
|
| Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/01/news_detail_001700.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe, France |
